16 results about "Camelid" patented technology

The invention relates to the technical field of nano antibodies, in particular to an anti-FcRH5 nano antibody and application thereof. The invention provides an anti-FcRH5 nano antibody with high affinity and specificity, and the anti-FcRH5 nano antibody is based on a single-domain heavy chain variable region structure from camelidae and has the advantages of small molecular weight, high stability, strong tissue penetrability, easiness in engineering modification and the like. The nano antibody specifically recognizes and is combined with a high-expression and stable-expression target spot on the surface of a multiple myeloma cell through a complementary determining region of the nano antibody. The nano antibody disclosed by the invention can be used as a core recognition element for constructing various treatment or diagnosis tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes and the like. According to the technical scheme, the technical problem that an anti-FcRH5 antibody with high quality and definite functionality is lacked in the prior art can be solved. The nano antibody provided by the invention has remarkable clinical transformation and industrialization advantages, and promotes multiple myeloma treatment to multi-target collaborative iteration.

Antibody-based binding agents derived from human and camelid immunoglobulins are described, as well as strains of yeast engineered to secrete the binding agents, and methods of treating and preventing Clostridium difficile infections using the engineered strains of yeast. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and / or toxin B and in some cases exhibit toxin neutralizing activity. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.

A method for selecting camelid nanobodies from an array library collected from B cells of a camelid animal immunized with an antigen is provided. The method comprises (a) (i)phenylalanine (F) at position 42 (IMGT number), and (ii)a short hinge, and (iii)two or more cysteines in the nanobody sequence, and (iv)glutamine (Q) at position 123 (IMGT number), and (v)a low immunogenicity index, and (vi)a non-conventional VHH derived from germline IGHV3, or valine (V) included at position 42 (IMGT number), and (vii)a non-conventional VHH derived from germline IGHV4, or isoleucine (I) included at position 42 (IMGT number), and (viii)histidine (H), aspartic acid (D), or glutamic acid (E) in the CDR region, and (ix)histidine (H), aspartic acid (D), or glutamic acid (E) in the top 3 amino acid residues of the nanobody sequence, the FR2 region, or the top 16 amino acid residues of the FR3 region, and (x)tyrosine (Y) at position 42 (IMGT number), and a nanobody having a cyclic concave paratope structure arrangement, or (xi)phenylalanine (F) at position 42 (IMGT number), and a nanobody having a convex paratope structure arrangement, identifying a camelid nanobody having at least one of the features, and (b)measuring one or more biological activities of the nanobody identified in step (a).

The present disclosure relates to nanobodies, therapeutic agents, compositions and methods for the diagnosis, prevention, amelioration and treatment of henipaviral infections. Herein disclosed are camelid-derived nanobodies that specifically bind the F protein of both Nipah virus (NiV) and Hendra virus (HeV). The disclose nanobodies effectively bind and potently neutralise both of these viruses, making these nanobodies suitable therapeutic agents for the prevention or treatment of henipaviral infections.

The invention relates to antigen-binding polypeptides comprising the CDR1, CDR2 and CDR3 region of a VHH domain of a camelid heavy chain antibody. The polypeptides bind specifically to CD229 and are therefore suitable for the diagnosis as well as for the therapeutic and prophylactic treatment of diseases characterised by increased CD229 expression. Fusion proteins, conjugates and pharmaceutical compositions comprising the antigen-binding polypeptides are also disclosed. In addition, the invention relates to the use of such antigenbinding polypeptides in methods for detecting CD229 or CD229-expressing cells in a biological sample. Methods for purifying and concentrating CD229 or CD229-expressing cells using the antigen-binding polypeptides are also described.

The invention relates to the technical field of nano antibodies, in particular to an anti-FcRH5 nano antibody and application thereof. The invention provides an anti-FcRH5 nano antibody with high affinity and specificity, and the anti-FcRH5 nano antibody is based on a single-domain heavy chain variable region structure from camelidae and has the advantages of small molecular weight, high stability, strong tissue penetrability, easiness in engineering modification and the like. The nano antibody specifically recognizes and is combined with a high-expression and stable-expression target spot on the surface of a multiple myeloma cell through a complementary determining region of the nano antibody. The nano antibody disclosed by the invention can be used as a core recognition element for constructing various treatment or diagnosis tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes and the like. According to the technical scheme, the technical problem that an anti-FcRH5 antibody with high quality and definite functionality is lacked in the prior art can be solved. The nano antibody provided by the invention has remarkable clinical transformation and industrialization advantages, and promotes multiple myeloma treatment to multi-target collaborative iteration.

The invention relates to a particular modified camelid single chain antibody called VHHNPX and uses of VHHNPX in new methods for the efficient delivery of molecular cargos inside target cells (in particular neurons and eye retina cells). The invention further relates to a Neurovita short interfering peptide suitable for neuroprotection and neuroregeneration and uses thereof, in particular a Neurovita peptide short fragment encoding a PDZ-binding motif (PBM) inhibiting the PDZ domain of the human MAST2 & MAST1 enzymes. The invention also relates to polypeptides comprising this Neurovita short peptide, notably peptides further comprising a cell-penetrating molecule (CPM), and uses thereof.

The present invention relates to a method and device for sorting alpaca fibres, in which an automated device sorts the portions of fleece, which have been previously separated manually according to the diameter range, using an identification belt with transport rollers that move and align the portions. A pressure roller and a transparent glass plate ensure that the portions remain on a single horizontal plane for uniform analysis. An industrial photographic camera with a magnifying lens and a light source is used to capture microscopic images that are processed by artificial intelligence (AI) to sort the fibres according to their quality. The sorting belt, equipped with presence sensors and mechanical pistons, guides the portions to the correct containers, while a robotic arm collects and redirects incorrect samples for re-sorting.

Provided is a method of selecting a camelid nanobody from a library of camelid nanobody sequences collected from B cells from a camelid immunized with an antigen. The method comprises: (a) identifying a camelid nanobody that has at least one of the following features (i) a phenylalanine (F) at position 42 (IMGT numbering); (ii) a short hinge; (iii) two or more cysteines in the nanobody sequence; (iv) a glutamine (Q) at position 123 (IMGT numbering); (v) low immunogenicity metric; (vi) non-classic VHH derived from germline IGHV3 or a valine (V) at position 42 (IMGT numbering); (vii) non-classic VHH derived from germline IGHV4 or an isoleucine (I) at position 42 (IMGT numbering); (viii) a histidine (H), aspartic acid (D) or glutamic acid (E) in the CDR region; (ix) a histidine (H), aspartic acid (D) or glutamic acid (E) in the first three amino acid residues, the FR2 region, or the first sixteen amino acid residues of the FR3 region of the nanobody sequence; (x) a tyrosine (Y) at position 42 (IMGT numbering), and the nanobody having a loop, concave paratope structure configuration; or (xi) a phenylalanine (F) at position 42 (IMGT numbering), and the nanobody having a convex paratope structure configuration; and (b) measuring one or more biological activities of the nanobody identified in step (a).

The present invention relates to Camelidae heavy chain only variable domain (VHH) molecules that bind to TfR, coupling compounds comprising such VHH molecules and their use for transporting molecules of pharmaceutical interest to cells and organs, for example under pathological conditions of CNS or PNS, including cancer.

The invention relates to a particular modified camelid single chain antibody called VHHNPX and uses of VHHNPX in new methods for the efficient delivery of molecular cargos inside target cells (in particular neurons and eye retina cells). The invention further relates to a Neurovita short interfering peptide suitable for neuroprotection and neuroregeneration and uses thereof, in particular a Neurovita peptide short fragment encoding a PDZ-binding motif (PBM) inhibiting the PDZ domain of the human MAST2 & MAST1 enzymes. The invention also relates to polypeptides comprising this Neurovita short peptide, notably peptides further comprising a cell-penetrating molecule (CPM), and uses thereof.

Provided herein are human complement component 2 (C2) binding molecules and nucleic acid sequences encoding such molecules. In particular embodiments, provided herein are human C2-binding molecules (e.g., nanoantibodies) having first and optionally second single monomeric variable antibody domains (SMVAD) comprising certain CDRs, and methods of using such molecules in the treatment of complement-associated diseases (e.g., complement activation disorder diseases). In certain embodiments, the SMVAD comprises a camelidae animal, human, or humanized framework region.

This specification provides human differentiation antigen group 6 (CD6) binding molecules and nucleic acid sequences encoding such molecules. In certain embodiments, this specification provides a first single-monomer variable antibody domain (SMVAD) comprising a specific CDR and, optionally, a human CD6 binding molecule (e.g., a nanobody) having a second single-monomer variable antibody domain, and a method for treating T-cell-related diseases (e.g., cancer, e.g., T-cell lymphoma) using such molecules. In certain embodiments, the SMVAD comprises a camelid, human, or humanized framework region.

The present application relates to the technical field of nanobody, in particular to anti-FcRH5 nanobody and its application. The present application provides a kind of anti-FcRH5 nanobody with high affinity and specificity, which is based on the single domain heavy chain variable region structure of camelid origin, with the advantages of small molecular weight, high stability, strong tissue penetration, easy to be engineered and the like. The nanobody specifically recognizes and binds to the target point highly expressed and stably expressed on the surface of multiple myeloma cells through its complementarity determining region. The nanobody of the present application can be used as a core recognition element to construct a variety of therapeutic or diagnostic tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes. The technical scheme can solve the technical problem that there is a lack of high-quality, functionally clear anti-FcRH5 antibody in the prior art. The nanobody of the present application has significant clinical transformation and industrialization advantages, and promotes the treatment of multiple myeloma to multiple target points.

The invention provides competitive particles, such as virus-like particles, RNAs and DNAs for the treatment or prevention of viral infections and methods of using such particles for treating or preventing or reducing the risk of viral infections (or symptoms thereof) in a subject, such as a human or animal subject. For example, the method herein is a method of reducing or reducing the establishment of a zoonotic population of a virus in an animal, such as a livestock or wild animal (eg, a bat, camelid or a Pholidota (eg, a pangolin)).

The application provides a bactrian camel feed and a production method thereof, and the bactrian camel feed is composed of the following components in parts by weight: cottonseed meal 7-8 parts, soybean meal 7-8.5 parts, corn 23-27 parts, corn alcohol dregs 9-10 parts, corn gluten meal 3.5-5.5 parts, wheat flour 5.5-6.5 parts, corn germ meal 14-15 parts, wheat bran 9-10 parts, corn white skin 3.5-5.5 parts, palm fatty acid powder 3-4 parts, white sugar 1-1.5 parts, salt 1.5-2.5 parts, premix 0.2-0.4 parts. The bactrian camel feed of the application takes soybean meal and cottonseed meal as the protein source, provides multiple protein sources, has more comprehensive nutritional value, and supplements palm fatty acid powder in a targeted manner, improves the energy level, and further improves the milk yield of bactrian camels. The preparation method is simple, the application provides a special feed for bactrian camel breeding industry, which is comprehensive in nutrition, controllable in cost, and can significantly improve the milk production performance.